Number One With A Bullet: Eylea Takes Top Spot In Medicare Part B Drugs

02 Aug 2017

• By Michael McCaughan

Regeneron’s Eylea is the new holder of the number one spot in Medicare Part B prescription drug payments. It is also the fastest growing entrant on the top-ten list tracked by MedPAC. That is a sign of great commercial success – but could be an uncomfortable spotlight.

The annual Medicare Payment Advisory Commission update to the top 10 list of Medicare Part B prescription drugs has a new number one: Regeneron Pharmaceuticals Inc.’s Eylea.

MedPAC’s June 2017 data book (publicly released at the end of July) lists the macular degeneration therapy as...